RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+12.33%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$740M
AUM Growth
+$740M
(-5.5%)
Cap. Flow
-$98.9M
Cap. Flow
% of AUM
-13.36%
Top 10 Holdings %
Top 10 Hldgs %
29.49%
Holding
104
New
10
Increased
27
Reduced
49
Closed
9
Top Buys
| 1 |
Acadia Pharmaceuticals
ACAD
|
$10.2M |
| 2 |
Gilead Sciences
GILD
|
$9.33M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$9.05M |
| 4 |
Cencora
COR
|
$8.66M |
| 5 |
FLXN
Flexion Therapeutics, Inc.
FLXN
|
$6.55M |
Top Sells
| 1 |
Nektar Therapeutics
NKTR
|
$30.6M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$15.4M |
| 3 |
ABMD
Abiomed Inc
ABMD
|
$10.1M |
| 4 |
AET
Aetna Inc
AET
|
$9.86M |
| 5 |
CVS Health
CVS
|
$9.76M |
Sector Composition
| 1 | Healthcare | 90.07% |
| 2 | Financials | 0.19% |
| 3 | Technology | 0.17% |
| 4 | Energy | 0.14% |
| 5 | Consumer Discretionary | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $28.5M | 3.86% | 1,954,912 -1,051,950 | -35% | -$15.4M |
|
2
Esperion Therapeutics
ESPR
$448M
| $25.5M | 3.44% | 386,626 +74,823 | +24% | +$4.93M |
|
|
ADMS
3
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $23.5M | 3.17% | 692,913 -222,087 | -24% | -$7.53M |
|
4
Exelixis
EXEL
$10.1B
| $23M | 3.11% | 756,214 -293,786 | -28% | -$8.93M |
|
5
Vertex Pharmaceuticals
VRTX
$100B
| $22.8M | 3.08% | 152,204 -27,796 | -15% | -$4.17M |
|
|
6
Nektar Therapeutics
NKTR
$568M
| $21.1M | 2.85% | 353,503 -512,691 | -59% | -$30.6M |
|
|
7
Gilead Sciences
GILD
$140B
| $20.5M | 2.77% | 285,751 +130,200 | +84% | +$9.33M |
|
|
ALXN
8
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $18.2M | 2.45% | 151,863 -13,137 | -8% | -$1.57M |
|
9
Jazz Pharmaceuticals
JAZZ
$7.75B
| $18M | 2.43% | 133,436 +48,436 | +57% | +$6.52M |
|
|
SAGE
10
DELISTED
Sage Therapeutics
SAGE
| $17.3M | 2.34% | 104,930 +54,930 | +110% | +$9.05M |
|
|
CELG
11
DELISTED
Celgene Corp
CELG
| $16.8M | 2.28% | 161,412 +9,412 | +6% | +$982K |
|
12
UnitedHealth
UNH
$281B
| $16.6M | 2.25% | 75,500 -9,500 | -11% | -$2.09M |
|
|
ESRX
13
DELISTED
Express Scripts Holding Company
ESRX
| $16.5M | 2.23% | 221,483 -23,517 | -10% | -$1.76M |
|
|
ABMD
14
DELISTED
Abiomed Inc
ABMD
| $16.2M | 2.19% | 86,490 -53,748 | -38% | -$10.1M |
|
|
15
Cencora
COR
$56.5B
| $16M | 2.16% | 174,261 +94,261 | +118% | +$8.66M |
|
|
ITCI
16
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $15.7M | 2.12% | 1,084,581 -95,319 | -8% | -$1.38M |
|
17
Glaukos
GKOS
$5.5B
| $15.6M | 2.11% | 608,400 -39,396 | -6% | -$1.01M |
|
18
Incyte
INCY
$16.5B
| $15.5M | 2.09% | 163,703 +48,703 | +42% | +$4.61M |
|
19
AbbVie
ABBV
$372B
| $15.2M | 2.05% | 156,700 +16,700 | +12% | +$1.62M |
|
20
Humana
HUM
$36.5B
| $14.4M | 1.94% | 58,000 +17,000 | +41% | +$4.22M |
|
21
Medtronic
MDT
$119B
| $13.3M | 1.79% | 164,225 -49,890 | -23% | -$4.03M |
|
|
ARNA
22
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $13.1M | 1.77% | 385,642 -183,849 | -32% | -$6.25M |
|
23
BioMarin Pharmaceuticals
BMRN
$11.2B
| $12.5M | 1.69% | 139,849 -40,100 | -22% | -$3.58M |
|
24
Eli Lilly
LLY
$657B
| $12.1M | 1.63% | 142,859 +32,859 | +30% | +$2.78M |
|
25
Regeneron Pharmaceuticals
REGN
$61.5B
| $11.7M | 1.58% | 31,154 +9,154 | +42% | +$3.44M |
|